Health technology firm Royal Philips has collaborated with injection and infusion systems manufacturer Ypsomed for the development of new digital self-medication adherence monitoring services.
The services will be based on Philips’cloud-based HealthSuite digital platform and connected devices of Ypsomed.
Both firms have entered into a memorandum of understanding for new digital services, and intend to sign the definitive agreements in the fourth quarter of this year.
The new SmartServices will allow injection systems manufacturer to expand its medical device business by offering digital solution for medication adherence monitoring and smart device management to its pharmaceutical customers.
Ypsomed’s SmartServices will feature Philips’ HealthSuite digital platform, which is a cloud-based platform that allows to solve complex challenges in healthcare and offers tools and services for integration, digital lifecycle management and end-to-end security.
The new digital services will deal with a range of device-oriented challenges, as well as support self-medication services for patients across chronic disease states such as diabetes, multiple sclerosis and rheumatoid arthritis
Ypsomed Delivery Systems senior vice president Ulrike Bauer said: “Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data.”
Philips HealthSuite digital platform business leader Dale Wiggins said: “Integrating Ypsomed’s smart devices and data into the Philips HealthSuite ecosystem means pharma companies will be able to develop solutions that leverage HealthSuite’s secure, cloud-based services.
“It will shorten time-to-market, enable them to scale-up solutions in a secure HIPAA-compliant way, and allow them to integrate data from Ypsomed devices with other data sources to support many different value-added use cases.”
Ypsomed is said to be the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs.
The company markets its products under mylife Diabetescare brand to patients or through pharmacies and clinics, while under YDS Ypsomed Delivery Systems umbrella brand for business-to-business sales to pharmaceutical companies.
Headquartered in Burgdorf, Switzerland, the injection systems manufacturer operates a global network of manufacturing sites, subsidiaries and distributors.